Brookline Capital Markets Reiterates Buy Rating on Moderna (MRNA), Phase 2 Initiation Supports Moderna's Competitive Positive in the Market
Go back to Brookline Capital Markets Reiterates Buy Rating on Moderna (MRNA), Phase 2 Initiation Supports Moderna's Competitive Positive in the Market| Marina Biotech, Inc. (NASDAQ: MRNA) | Delayed: 64.46 +1.14 (1.80%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $63.32 | 52 Week High | $0.52 | |||
| Open | $64.78 | 52 Week Low | $0.08 | |||
| Day High | $65.53 | P/E | N/A | |||
| Day Low | $62.91 | EPS | $-3.80 | |||
| Volume | 3,979,514 | |||||
